SuperworthIllumina EPS ILMN
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 28, 2026
- $5.38
- Latest quarter, Q2 FY26
- $1.35
- −9% on a year earlier
- Fiscal year 2025
- $5.47
Illumina's earnings per share was $5.38 over the twelve months to Jun 28, 2026, down 32% on a year earlier.
In its latest quarter, Q2 FY26, it was $1.35, down 9% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 4% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $5.47 | n/a |
| FY2024 | −$7.67 | n/a |
| FY2023 | −$7.34 | n/a |
| FY2022 | −$28.00 | −654% |
| FY2021 | $5.05 | +14% |
| FY2020 | $4.44 | −34% |
| FY2019 | $6.75 | +21% |
| FY2018 | $5.56 | +13% |
| FY2017 | $4.92 | +57% |
| FY2016 | $3.13 | +1% |
| FY2015 | $3.10 | +31% |
| FY2014 | $2.37 | +176% |
| FY2013 | $0.86 | −24% |
| FY2012 | $1.13 | +82% |
| FY2011 | $0.62 | −28% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.35 | −9% | $5.38 | |
| Q1 FY26 | $0.87 | +6% | $5.52 | |
| Q4 FY25 | $2.18 | +85% | $5.47 | |
| Q3 FY25 | $0.98 | −78% | $4.47 | |
| Q2 FY25 | $1.49 | n/a | $7.91 | |
| Q1 FY25 | $0.82 | n/a | −$6.06 | |
| Q4 FY24 | $1.18 | n/a | −$7.67 | |
| Q3 FY24 | $4.42 | n/a | −$9.96 | |
| Q2 FY24 | −$12.48 | n/a | −$19.15 | |
| Q1 FY24 | −$0.79 | −4050% | −$8.15 | |
| Q4 FY23 | −$1.11 | n/a | −$7.34 | |
| Q3 FY23 | −$4.77 | n/a | −$7.12 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Illumina's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ILMNIllumina | $5.38 | −32% a year |
| IDXXIDEXX Laboratories | $14.22 | +18% a year |
| WATWaters | $4.01 | −64% a year |
| IQVIQVIA | $8.06 | +17% a year |
| AAgilent Technologies | $5.09 | +19% a year |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| LHLabcorp | $12.09 | +33% a year |
| MEDPMedpace | $17.05 | +27% a year |
| RVTYRevvity | $2.10 | −11% a year |
| DHRDanaher | $5.63 | +20% a year |
| Peer median | $8.73 |
Where Illumina ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Illumina
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.